Effectiveness of high-dose infusions of methotrexate followed by leucovorin in carcinoma of the head and neck.
D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy*; D005260:Female; D006258:Head and Neck Neoplasms / Q000188:drug therapy*; D006801:Humans; D007263:Infusions, Parenteral; D007573:Jaw Neoplasms / Q000188:drug therapy*; D007822:Laryngeal Neoplasms / Q000188:drug therapy; D002955:Leucovorin / Q000008:administration & dosage* / Q000009:adverse effects; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000188:drug therapy*; D009362:Neoplasm Metastasis / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy; D010255:Paranasal Sinus Neoplasms / Q000188:drug therapy; D010610:Pharyngeal Neoplasms / Q000188:drug therapy; D012469:Salivary Glands; D013921:Thrombocytopenia / Q000139:chemically induced; D014062:Tongue Neoplasms / Q000188:drug therapy; D014067:Tonsillar Neoplasms / Q000188:drug therapy
D002955:Leucovorin; D008727:Methotrexate